#Utidelone

Key findings:
• mPFS 3.97 mo, OS 20.63 mo
• ORR 8.4%, CBR 33.5%
• Most common AE: peripheral neuropathy (55.2%)
• Higher PN risk with unresolved prior PN or day1–5 infusion schedule
Overall: UTD1 offers a viable option with manageable toxicity.
#CancerResearch #Utidelone

FDA Grants Third Orphan Drug Designation to Biostar Pharma's Utidelone for Pancreatic Cancer Treatment Biostar Pharma's Utidelone receives Orphan Drug Designation from the FDA to treat pancreatic cancer, highlighting its potential benefits against this difficult disease.

FDA Grants Third Orphan Drug Designation to Biostar Pharma's Utidelone for Pancreatic Cancer Treatment #United_States #San_Francisco #pancreatic_cancer #Utidelone #Biostar_Pharma

Biostar Pharma Initiates Advancement in Cancer Treatment with New Clinical Trials of Utidelone Capsule Biostar Pharma has begun two significant Phase II/III clinical trials for the innovative Utidelone Capsule, targeting advanced gastric and ovarian cancers, marking a major step in oncology drug development.

Biostar Pharma Initiates Advancement in Cancer Treatment with New Clinical Trials of Utidelone Capsule #United_States #San_Francisco #oncology #Biostar #Utidelone